Stop the War on Drugs
In December 2005, Eli Lilly pled guilty to a criminal indictment from the Justice Department and paid $36 million in fines and “disgorgement” of its ill-gotten gains. The company’s crime was mounting a concerted effort to inform doctors that, according to leading medical authorities, the firm’s estrogen-modulating drug Evista substantially reduced the risk of invasive breast cancer in postmenopausal women. The finding came from a series of landmark national studies, some eventually touted by government research. So why the criminal charge?